Itamar Medical wins China marketing approval
"Entry into the Chinese medical devices market is an opportunity, given the market's size."
The company said that entry into the Chinese medical devices market is an opportunity, given the market's size.
The European Medicines Agency (EMEA) and US Food and Drug Administration (FDA) have already approved both the EndoPat and WatchPat.
Itamar Medical's share price rose 6.6% by mid-afternoon to NIS 2.10, giving a market cap of NIS 263 million.
Published by Globes [online], Israel business news - www.globes-online.com - on March 27, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options